A study to assess safety, tolerability and PK of AZD2171 and chemotherapy on patients with solid tumors
Study identifier:D8480C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase 1, Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2171 and selected Chemotherapy Regimens when given in combination to Patients with Advanced Solid Tumors
Medical condition
advanced solid tumor
Phase
Phase 1
Healthy volunteers
No
Study drug
AZD2171, FOLFOX, Pemetrexed, Irinotecan (administered with & without Cetuximab), Docetaxel
Sex
All
Actual Enrollment
104
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jan 2005
Primary Completion Date: 01 Nov 2007
Study Completion Date: 01 Jun 2011
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Jane Robertson
AstraZeneca
